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Abstract 
A fast and frugal generic tool can provide decision support to 
those making decisions about individual cases, particularly 
clinicians and clinical commissioners operating within the 
budget and time constraints of their practices. The multi-
national Generic Rapid Evaluation Support Tool (GREST) is 
a standard preference-sensitive Multi-Criteria Decision 
Analysis-based tool, but innovatory insofar as an equity 
criterion is introduced as one of six. Equity impact reflects the 
number of population QALYs lost or gained in moving from 
Old (current intervention) to New (contemplated intervention). 
In the exemplar UK implementation Claxton’s NHS 
Willingness to Pay per QALY is the numeraire. Any weight 
from 0 to 100% may be assigned to the equity criterion but its 
presence affirms that it is persons-as-citizens who experience 
any opportunity harms or benefits arising from actions within 
the health service commons. A fully-operational but 
demonstration-only version is available  on open access, as 
proof of concept and method. 
Keywords: 
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Introduction 
Clinicians and clinical commissioning groups are routinely 
making decisions about the use of new and/or expensive 
interventions for individual cases, including patients with 
multiple morbidities. They may be facing an increasing 
number of such decisions in the UK, if the recent High Court 
decision regarding off-label/licence drugs is upheld 
(https://www.bbc.co.uk/news/health-45588983).  
We perceive a major gap in the support available for such 
decisions. NICE-type evaluations can cover only a tiny 
minority of interventions and their remit is currently restricted 
to on-label use. Decision aids developed according to 
normative standards such as IPDASi [1] are very limited in 
coverage, constitute information aids rather than decision 
support tools that produce an opinion, and rarely introduce 
budget considerations. Guideline recommendations, such as 
those produced by GRADE, cannot, by definition, reflect 
individual preferences, only group or sub-group averages, and 
leave the decision maker analytically unsupported in the task 
of processing the extensive summary of evidence at the point 
of decision. 
 
Whenever a proposed NEW intervention is to be 
comparatively evaluated against a current OLD one within 
time and resource constraints, a flexible, rapid, generic and 
inexpensive decision support tool is needed.  
The required tool must be practical and useful. It must meet 
the SMART criteria - Specific, Measurable, Achievable, 
Relevant, and Timely - to the extent each of these are 
reasonable in the given decision context. More simply, the 
decision support must be ‘fast and frugal’. It must be pitched 
at the most appropriate point (trade-off) on the ‘rigour-
relevance’ continuum. It will therefore be a long way from a 
highly analytical NICE-type evaluation in one direction, but 
also far removed from an expert deliberation-based guideline 
in the other. While endorsing long term efforts to develop 
normatively superior methods of linking evidence and clinical 
practice [2-6] or dealing with the complexities of value-based 
care [7-8] we have the simple but limited ambition of 
providing a rapid and practical method of improving on the 
present decision making process, whatever it is. The tool will 
not seek to replace or deter the development of superior tools, 
but reflect the belief that the normatively best, or even 
normatively better, may be the enemy of the empirically better 
– a point well-accepted in relation to drugs and devices, not 
yet for decisions. Evaluations should reflect this and use the 
actual process they would replace as comparator. 
Method 
Multi-Criteria Decision Analysis (MCDA) can provide the 
basis for such fast and frugal decision support tools. Given 
their basis in this technique they can provide an opinion on the 
worth of each Option (one of the actions that can be taken) by 
combining its Ratings (how well it performs on relevant 
Criteria) with the criteria Weightings (how important each 
criterion is relevant to the others), making the opinion a 
preference-sensitive one. Introductory materials and numerous 
examples of the implementations of MCDA in the decision 
support context are available at http://cafeannalisa.org.uk 
including the short video ‘Powtoons’. In the space available 
and to avoid duplication we leave further details of Method to 
the following Results section and the online tool introduced 
there. 
In Multi-Criteria Decision Analysis-based tools, it is entirely 
feasible to include an equity outcome criterion and our 
proposed tool, implemented in the Annalisa template [9], does 
this. However, we emphasize that this innovation occurs in the 
context of a more extended, multicriterial analysis, otherwise 
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the tool will not be appropriate in person/citizen-centred 
healthcare decision making. 
 
Result 
 
The Generic Rapid Evaluation Support Tool (GREST) is 
presented here as proof of concept and method, based on 
internal testing, and as the basis for feedback in relation to 
future development and implementation. 
The two options in GREST are OLD (the current intervention, 
such as usual/standard/current care) and NEW (the 
contemplated replacement). The six criteria in the default 
prototype are: 
• A condition/decision-specific Biomarker (e.g. Bone 
Mineral Density) 
• A condition/decision-specific Function(al) Index (e.g. 
Six Minute Walk Test) 
• Option (test/treatment) Side effects 
• Option (test/treatment) Burden (e.g. arising from 
frequency and mode of delivery of medication) 
• Health-Related Quality of Life (HRQOL) 
• Equity (reflecting the Harm/Foregone Benefits to 
Others in ‘North-East’ cases and Benefit/Foregone 
Harm to Others in ‘South-West’ ones – see below) 
It will be noted that Life Expectancy is not a criterion in the 
current GREST, so if there is any effect on this from the new 
intervention, it would need to be discussed separately in the 
light of the GREST opinion.  It will also be noted that 
monetary cost is not a separate criterion, being introduced 
only through the sixth, equity, criterion. 
To engage with the tool and understand the method underlying 
it, go to https://ale.rsyd.dk (enter 1513 as survey ID). This 
version is in English and uses the EQ-5D-5L tariff for 11 
countries to establish Health-Related Quality of Life 
(HRQOL) values used in deriving the ratings for both the 
HRQOL and Equity criteria. Nine tariffs are from 
https://euroqol.org/eq-5d-instruments/eq-5d-about/valuation-
standard-value-sets/crosswalk-index-value-calculator[10]; 
others tariffs included are for Poland [11] and China [12], 
This is a demo version provided as a proof of concept and 
method on open access. Only anonymous, non-confidential 
data should be entered. No responsibility is taken for data 
security.  
The performance ratings of OLD and NEW on the first five 
criteria in GREST are elicited in whatever way is compatible 
with the clinician’s or clinical commissioning group’s practice 
timescale and resources. The Ratings for both OLD and NEW 
should be the BEANs (Best Estimates Available Now) and 
hence as evidence-based as is possible, and as expertise-based 
as is necessary, within the actual resource and time constraints 
of the decision makers. The person/patient is to be regarded as 
the expert on Treatment Burden. The derivation of the ratings 
for the equity criterion is explained in a separate sub-section 
below. 
The relative importance Weighting of each criterion, including 
equity, is elicited on a 0-100% scale, where 0 indicates of no 
importance and 100% of extreme importance. The six 
responses are summed and percentaged to give and display the 
set of provisional criterion weights that add to 100%. In this 
interactive tool they may be changed by cursor on inspection 
of their graphical display. More sophisticated weight 
elicitation procedures, such as swing weights or discrete 
choice experiments, may have greater normative appeal than 
Visual Analog Scales, but lack either individual applicability 
or practicality in the typical time and resource scale 
contemplated. 
 
 
 
Figure 1: North-East Case with 5.9% Equity Weight 
 
 
 
Figure 2: North-East Case with 50% Equity Weight 
 
The GREST output is in the form of a ‘deciographic’ - a single 
screen showing all Ratings, Weightings, and the evaluation 
Scores for OLD and NEW. As in all standard MCDA 
applications, the Score combines the relative importance 
criterion Weightings with the evidence- and expertise- 
informed option performance Ratings, by the Expected Value 
algorithm.  
Giving 50% weight to equity in Figure 2 (bottom) rather than 
the 5.9% in Figure 1 (top) flips the opinion to OLD. 
The ratings in the above example are purely illustrative. We 
imagine NEW to be superior on Biomarker, Function, and 
HRQOL, but inferior on Side Effects and Treatment Burden – 
and, by the definition of a ‘North-East’ GREST, it produces 
net ‘Harm to Others’. The 50% Equity rating for OLD reflects 
complete uncertainty about its value. In the Ratings panel a 
longer bar always means better and in the Weightings panel a 
longer bar always means more important. 
 
The Equity Criterion 
 
Person-centred care – and value-based healthcare - is not all 
about the rights of the person. Persons are also citizens who 
have responsibilities and duties within a resource-constrained 
public health service. Only by applying a generic outcome 
measure as a criterion within a personalised multi-criterial 
decision analysis can we move to the coherent involvement of 
equity in decision making about clinical cases. In GREST, the 
equity outcome criterion is defined and measured as the 
Harms or Benefits to Others created in moving from OLD to 
NEW in a resource-constrained service. In measuring these, 
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any condition-specific outcome such as cancer 
mortality/morbidity, as contrasted with all-cause 
mortality/morbidity, is ruled out as equity-irrelevant. 
We have chosen Health-Related Quality of Life (HRQOL) as 
our generic equity outcome measure, the current GREST 
explicitly eschewing evaluations where NEW alters life 
expectancy. We use EQ-5D-5L as the HRQOL metric, though 
the method is not tied to any specific instrument. 
Where the NEW intervention is more expensive than the OLD, 
but also more effective, we are in the North-East quadrant of 
the Cost-Effectiveness plane. There will be ‘opportunity 
harms’ (foregone benefits) to others, usually anonymous and 
unidentifiable, as a result of substituting NEW for OLD. 
Where a NEW intervention is less expensive than the OLD, 
but also less effective, we are in the South-West quadrant of 
the Cost-Effectiveness plane, the only one recognized in 
NICE, where lower effectiveness is disallowed as a source of 
improved cost-effectiveness. This restriction of cost-
effectiveness to incremental cost-effectiveness constitutes 
political interference with the implementation of a neutral 
technique [13]. In this quadrant there will be ‘opportunity 
benefits’ (foregone harms) to others, usually anonymous and 
unidentifiable, as a result of substituting NEW for OLD. 
In measuring the foregone benefits and harms in the UK 
context, we use Karl Claxton’s estimate of the NHS’s revealed 
willingness to pay (WTP) for a Quality-Adjusted Life Year 
(QALY) of £12,000. ‘The central or mean estimate of £12,936 
is likely, if anything, to be an overestimate’, hence our use of 
£12,000. [14] (p4).  
Equity impact is calculated as the number of QALYs that 
would be moved from Others to the recipient of the NEW 
intervention. So, if the NEW intervention (assuming no life 
expectancy effect) costs £24,000 per year compared with 
£1,600 for the current OLD treatment (Extra cost = £22,400), 
and it improves HRQOL from 0.23 to 0.59 (QALY gain = 
0.36), the Equity impact (Harm to Others) created by adopting 
NEW is calculated as:  
£22,400 / 0.36 = £62,222 per QALY 
£62,222 / £12,000 = 5.2. 
The generation of the 1 QALY involved in substituting NEW 
for OLD for a single (identifiable) person creates a QALY loss 
of 5.2 to anonymous others elsewhere in the service. At the 
population level there is a net loss of 4.2 QALYs from the 
shift. This loss may all be borne by one anonymous person, or 
be distributed as lost quality-adjusted weeks or days across 
small or large numbers of people. The fact is that this 
distribution is unknown. (The issue of ‘statistical compassion’ 
is raised in the final section.) 
If we reverse the OLD and NEW data and move into the 
South-West quadrant of decremental cost-effectiveness, the 
arithmetic is the same but the effect the opposite. Substituting 
NEW for OLD now creates a QALY gain of 5.2 to anonymous 
others elsewhere in the service. At the population level there is 
a net gain of 4.2 QALYs.  
To map the QALY movement on to the required 0-1 ratio 
scale for the MCDA-based tool, we take its reciprocal, 
subtracting this from 1 in the South-West case. Moving 5.2 
QALYs becomes 0.193 in the NE case (Figures 1 and 2) and 
0.807 in the SW (Figures 3 and 4). 
 
 
 
Figure 3: South-West case with 5.9% equity weight 
 
 
 
Figure 4: South-West case with 50% equity weight 
 
The above screens result from reversing the data in the earlier 
example, making NEW a South-West intervention, where it 
produces lower HRQOL but at greatly reduced cost, in 
contrast to the North-East situation where it produces the same 
amount of higher HRQOL but at greatly increased cost. 
Giving about 6% weight to equity in Figure 3 (top) is 
insufficient to shift the verdict in favour of NEW, but 
assigning 50% weight in Figure 4 (bottom) clearly does so. 
What can we conclude about the change in equity in these two 
situations? The most reasonable assumption is that the 
anonymous others who are either gainers or losers from NEW 
will be randomly distributed. Under this assumption and 
assuming an equity rating for OLD of 50% (reflecting 
complete uncertainty), the net effect of NEW will be to 
increase inequity if it is a North-East intervention (replacing 
the less costly and less effective OLD) and reduce inequity if 
it is a South-West one (where it is less costly and less effective 
than OLD). 
The magnitude of the effects will be a function of the numbers 
in the particular clinical case. But we can note that at a service 
level, the potentially very large numbers of opportunity harms 
from NE interventions may add up to a massive increase in 
inequity while the failure to consider SW interventions can 
add up to a huge potential failure to reduce inequity. The same 
applies in the individual screening context. 
 
Discussion 
 
Claxton makes our basic point in relation to NICE decisions 
about new drugs, where the threshold being used is far above 
the average observed WTP for a QALY of £12.000, but it is 
equally pertinent at the clinical/clinical commissioning level. 
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“The evidence suggests that more harm than good is being 
done, but it is the unidentified and unrepresented NHS patients 
who bear the true (health) opportunity costs. Although finding 
reasons to approve new drugs is undoubtedly politically 
expedient, this cannot be ethically literate, because the 
interests of NHS patients, whether they are identifiable or not, 
are just as real and equally deserving of the type of care and 
compassion that can be offered by a collectively funded health 
care system. It is to be hoped that NICE will begin to place the 
unidentified NHS patients who bear the real opportunity costs 
at the heart of its deliberative process.” [15] (p6). 
The GREST tool does not mandate any amount of concern 
with the impact on others, but it does mandate a statement of 
the weight to be assigned to it, in the 0 to 100% range, in 
generating the opinion of the decision support tool. As 
persons-as-citizens, we incur both a right and responsibility to 
be informed of the impact on others of our use of the health 
service commons in self-producing and co-creating health 
[16].   
Objections to introducing a societal element into clinical 
decisions can be expected from clinicians as well as patients, 
but rejected on the ground that equity is a social matter for all 
citizens, and it is not for a profession to decide as they should 
to be able to ‘protect their patients’ from concern with it. In 
any case, a healthcare budget-holder cannot escape this wider 
responsibility for all those within their aegis. 
Treating any individual person as a means to achieve some 
population policy end– to reduce the incidence of this, 
increase the uptake of that – has to be rejected even if it is in 
their perceived individual best interests. (Infectious diseases 
are an exception where the law rightly takes away the right of 
an individual to directly jeopardise the health of others.) But 
neither is it ethical for the person as citizen to be left in – or 
allowed to opt into - complete ignorance as to the impact on 
others, in whatever direction. An empirical resolution of the 
clash between individual and community [17] is brought no 
nearer by simple repeated noting of its existence, or by 
attempts to solve it solely at the collective level, leaving the 
individual uninvolved in any direct way. 
The person is not only a citizen, but usually a member of a 
family or other group of significant others. Nothing said here 
is meant to imply that the person will not wish to take the 
feelings and consequences for these near others into their 
decision making.  Nor to imply that the benefits of a ‘family 
focus’ in provider care should be ignored or underestimated. 
We merely note that if relatives are driving demands to ‘do 
everything possible’ against the perceived implicit, or 
explicitly expressed, wishes of the patient, this transparent 
support will be helpful in empowering the patient. 
Both the ethical requirements of ‘patient-centred’ care and the 
legal requirements of ‘reasonable patient’ care suggest that the 
introduction of ‘equity’ into clinical practice guidelines, 
recently advocated [18-21], is not an appropriate way to go. 
The GRADE subgroup propose that guidelines panels 
recommend that clinical practitioners ’consider’ the ways in 
which an individual patient may be affected through being a 
member of a ‘disadvantaged’ group. However, this seems to 
be ethically suspect, insofar as it could potentially distort the 
personalized option ratings for, and personal criterion 
weightings of, the specific individual. The case for a 
personalized decision analytic approach using individualised 
ratings and weightings is well made by Wasfy and colleagues 
[22] and not satisfactorily refuted by Lightner [23]. GREST is 
on offer whether or not guidelines panels were to abdicate 
from making a recommendation in the face of uncertainty 
[24]. 
Everyone seeking to participate in the equity debate is 
confronted by the sociopsychological phenomenon, 
emphasised by Williams and Cookson, among others, of the 
difficulty individuals have in relating to the thousands of 
anonymous others who have equal rights in the health service 
commons.  
“For many people [the] notion of ‘statistical compassion’ 
seems to create both intellectual and psychological difficulties. 
It is as if personal empathy with one or two individuals is 
possible, but, paradoxically, if many individuals are involved, 
this capacity to empathise diminishes. This difference between 
focusing on groups and focusing on individuals also 
distinguishes economists (and managers) from clinicians and 
others dealing with people at an individual level. The latter 
often claim that they are under an ethical duty to do 
everything possible for the person in front of them no matter 
what the consequences might be for everybody else. If this 
assertion is taken at its face value, it would imply that 
clinicians should ignore their responsibilities for the welfare of 
their other patients except when that patient is in front of 
them. It seems most unlikely that any clinician would actually 
behave in that way, so perhaps the statement should not be 
taken at its face value, but regarded instead as part of the 
rhetoric of medical practice, designed to bolster the doctor-
patient relationship. But whatever may be the role of such 
statements, it is clear that in a public policy context, where 
distributive justice is an explicit objective, it is clearly not 
ethical for a clinician to ignore the consequences of his or her 
actions concerning the treatment of one patient for the health 
of other patients for whom the system is also responsible.” 
[25] (p1866).  
Conclusion 
The individual can only self-produce their health, and co-
create it with healthcare professionals and significant others, 
within the wider environment and socioeconomic constraints 
in which they live and work. Most of the recent advances in 
key health indicators (e.g. life expectancy) are attributable to 
sectors other than healthcare, so that the creation of health and 
health equity needs to be approached within a much wider and 
comprehensive framework [26]. Equitably, cost-effective, 
cross-sectoral public health policies are an essential 
complement to any changes in clinical decision making [27].  
However, the transparent introduction of equity considerations 
into decision making in relation to individuals can play an 
important role in affirming the social nature of a public health 
service. A public health service is not a private health service. 
It is ultimately the person-as-citizen who is experiencing any 
opportunity harm or benefit that arises from an action within 
the health service commons [28]. All health service decision 
makers should therefore be showing the ‘statistical 
compassion’ appropriate to their level of responsibility. 
GREST provides a simple way to allow the opportunity 
implications of a decision to be highlighted, but then set at 
whatever level is desired - including zero. 
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